Needham has recently initiated Hims & Hers Health Inc (HIMS) stock to Buy rating, as announced on August 22, 2024, according to Finviz. Earlier, on August 9, 2024, Imperial Capital had reduced the stock rating. Citigroup also reduced Neutral rating with a price target of $20. Additionally, Jefferies reduced Hold rating on April 16, 2024, with a target price of $15. Canaccord Genuity analysts, in their report published on April 10, 2024, also initiated Buy rating for Hims & Hers Health Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Hims & Hers Health Inc (HIMS) Stock Trading Recap
On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $22.15 which represents a slight increase of $0.59 or 2.74% from the prior close of $21.56. The stock opened at $21.76 and touched a low of $21.1 during the day, reaching a high of $22.16. The volume of shares traded was 6.34 million falling short of the average volume of 9.93 million.
Sponsored
HIMS Stock Performance and Moving Averages
In recent trading, Hims & Hers Health Inc (HIMS) stock price has shown some volatility, fluctuating 18.51% over the last five trades and 30.91% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 86.13%, and it has gained 8.90% in the previous three months. Currently, HIMS is trading at 16.35%, 30.53%, and 41.12% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, HIMS, a Consumer Defensive sector stock, is trading -13.95% below its 52-week high but remains 292.04% above its 52-week low. The Average True Range (ATR) (14 days) of 1.3 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Hims & Hers Health Inc’s Profitability and Valuation Ratios
Hims & Hers Health Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 0.64% and a profit margin of 1.70%, with a gross margin of 86.13%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Hims & Hers Health Inc’s market capitalization stands at $4.79 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 296.12, assessing the company’s valuation relative to its earnings. The forward P/E ratio, which uses projected earnings for the next financial year, is 29.81. Additionally, the Price-to-Sales Ratio is 4.49, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 13.27, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 19.68% of Hims & Hers Health Inc (HIMS)’s shares, while financial institutions hold 56.95%.
Notable insider trades include Chi Michael, Chief Commercial Officer at Hims & Hers Health Inc (HIMS), who sold 75493 shares on Oct 15 ’24, at $22 each, totaling $1.66 million. On Oct 14 ’24, Okupe Oluyemi, Chief Financial Officer, sold 269739 shares for $20.31 each, amounting to $5.48 million. Additionally, on Oct 07 ’24, Baird Melissa sold 58750 shares at $19.57 each, generating $1.15 million.
